Acute kidney injury in patients treated with immune checkpoint inhibitors

Autor: Gupta, S., Short, S.A.P., Sise, M.E., Prosek, J.M., Madhavan, S.M., Soler, M.J., Ostermann, M., Herrmann, S.M., Abudayyeh, A., Anand, S., Glezerman, I., Motwani, S.S., Murakami, N., Wanchoo, R., Ortiz-Melo, D.I., Rashidi, A., Sprangers, B., Aggarwal, V., Malik, A.B., Loew, S., Carlos, C.A., Chang, W.T., Beckerman, P., Mithani, Z., Shah, C.V., Renaghan, A.D., Seigneux, S.D., Campedel, L., Kitchlu, A., Shin, D.S., Rangarajan, S., Deshpande, P., Coppock, G., Eijgelsheim, M., Seethapathy, H., Lee, M.D., Strohbehn, I.A., Owen, D.H., Husain, M., Garcia-Carro, C., Bermejo, S., Lumlertgul, N., Seylanova, N., Flanders, L., Isik, B., Mamlouk, O., Lin, J.S., Garcia, P., Kaghazchi, A., Khanin, Y., Kansal, S.K., Wauters, E., Chandra, S., Schmidt-Ott, K.M., Hsu, R.K., Tio, M.C., Sarvode Mothi, S., Singh, H., Schrag, D., Jhaveri, K.D., Reynolds, K.L., Cortazar, F.B., Leaf, D.E.

BACKGROUND: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. METHODS: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::a58dc5e5578ebe5ece49ed903dc983c7
http://edoc.mdc-berlin.de/20988/7/20988suppl.pdf

1767P Outcomes after first line therapy in metastatic bladder and upper tract cancer

Autor: Furtado O'Mahony, L.F., Jackson-Spence, F., Toms, C., Flanders, L., Hockings, H.A., Choy, J., Powles, T.B., Szabados, B.E.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1346-S1346

1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre

Autor: Dolly, S., Russell, B., Moss, C.L., Tsotra, E., Gousis, C., Roca, J., Sita-Lumsden, A., Khan, M., Josephs, D., Zaki, K., Smith, D., Michalarea, V., Kristeleit, R., Enting, D., Flanders, L., Lei, M., Sawyer, E., Spicer, J., Ross, P., Montes, A., Van Hemelrijick, M.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S1149-S1149

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis

Autor: Kennedy, N A, Warner, B, Johnston, E L, Flanders, L, Hendy, P, Ding, N S, Harris, R, Fadra, A S, Basquill, C, Lamb, C A, Cameron, F L, Murray, C D, Parkes, M, Gooding, I, Ahmad, T, Gaya, D R, Mann, S, Lindsay, J O, Gordon, J, Satsangi, J, Hart, A, McCartney, S, Irving, P, Lees, C W

Publikováno v: Kennedy, N A, Warner, B, Johnston, E L, Flanders, L, Hendy, P, Ding, N S, Harris, R, Fadra, A S, Basquill, C, Lamb, C A, Cameron, F L, Murray, C D, Parkes, M, Gooding, I, Ahmad, T, Gaya, D R, Mann, S, Lindsay, J O, Gordon, J, Satsangi, J, Hart, A, McCartney, S & Irving, P & Lees, C W 2016, ' Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease : an observational study, plus systematic review and meta-analysis ', Alimentary Pharmacology and Therapeutics . https://doi.org/10.1111/apt.13547

BACKGROUND: Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::015eddb26e5d28787e841e2220a18751
https://pubmed.ncbi.nlm.nih.gov/28073137